The only common PCSK9 variant in the UK (p.Asp374Tyr) occurs in about 2% of mutation-positive FH patients, while the most common loss-of-function mutation inactivating the PCSK9 protein (p.Arg46Leu) can be found in approximately 3% of European individuals [7]. Here, PCSK9 is linked to familial hyperaldosteronism.